Zotatifin And EIF4A Platinum Helix Inhibition In Resistant AdvancedTNBC

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07783659
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced TNBC
  • EIF4A
  • Phase IB
  • Platinum Helix Inhibition
  • Zotatifin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zotatifin — DRUG
    Given by IV
  • carboplatin — DRUG
    Given by IV

Study Details

To find the optimal (best) recommended dose of zotatifin and carboplatin to treat patients with metastatic or recurrent TNBC.

Key Dates

First listed
Aug 25, 2026
Start date
Feb 12, 2027
Status verified
Aug 2026
Primary completion
Jun 30, 2030
Completion
Jun 30, 2032

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ZOT-CAR: Phase 1b Treatment with Zotatifin + Carboplatin

Primary Outcome Measure

Safety and adverse events (AEs). [ Time Frame: Through study completion; an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD Anderson Cancer CenterHoustonTexas77030
Bora Lim, MD
[email protected]
713-745-0689
Bora Lim, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
UT MD Anderson Cancer Center· Houston, TX

Related Studies